연구동향 분석
박사

RNAi therapeutics delivery strategies with non-viral vectors for targeted cancer therapy

곽기정 2020년

논문상세정보
인용/피인용
' RNAi therapeutics delivery strategies with non-viral vectors for targeted cancer therapy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • anti-angiogenic therapy
  • cancerimmunotherapy
  • carrier-free gene therapy
  • non-viral vector
  • rnai
  • tumor-targeting
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
68 0

0.0%

' RNAi therapeutics delivery strategies with non-viral vectors for targeted cancer therapy' 의 참고문헌

  • siRNA Delivery Strategies : AComprehensive Review of Recent Developments
    7 ( 4 ) [2017]
  • miR-573 regulates melanoma progression by targeting the melanoma cell adhesion molecule
    30 ( 1 ) ( [2013]
  • an epithelial-mesenchymal transition inducer , is associated with triple-negative breast cancer
    109 ( 4 ) ( [2012]
  • ``Control of translation and mRNA degradation by miRNAs and siRNAs .
    20 ( 5 ) ( [2006]
  • [82] L. Khoja, M.O. Butler, S.P. Kang, S. Ebbinghaus, A.M. Joshua, Pembrolizumab, J ImmunotherCancer 3 (2015) 36.
    3 (36 . [2015]
  • [7] J. Krutzfeldt, N. Rajewsky, R. Braich, K.G. Rajeev, T. Tuschl, M. Manoharan, M. Stoffel, Silencing of microRNAs in vivo with ¡®antagomirs¡¯, Nature 438(7068) (2005) 685-689.
    438 ( 7068 ) ( [2005]
  • [70] J. Couzin-Frankel, Breakthrough of the year 2013. Cancer immunotherapy, Science 342(6165) (2013) 1432-3.
  • [62] R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, R.S. Mannel, H.D. Homesley, J. Fowler, B.E. Greer, M. Boente, M.J. Birrer, S.X. Liang, G.O. Grp, Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer, New Engl J Med 365(26) (2011) 2473-2483.
  • [51] J. Folkman, M. Klagsbrun, Angiogenic factors, Science 235(4787) (1987) 442-7.
    235 ( 4787 ) ( [1987]
  • [50] J. Folkman, D.M. Long, Jr., F.F. Becker, Growth and metastasis of tumor in organCulture,Cancer 16 (1963) 453-67.
    16 ( [1963]
  • [49] H.Y. Yoon, S. Son, S.J. Lee, D.G. You, J.Y. Yhee, J.H. Park, M. Swierczewska, S. Lee, I.C. Kwon, S.H. Kim, K. Kim, M.G. Pomper, Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA, Sci Rep 4 (2014) 6878.
  • [3] D. Haussecker, Current issues of RNAi therapeutics delivery and development, J Control Release 195 (2014) 49-54.
  • [38] R.A. Gatenby, R.J. Gillies, A microenvironmental model ofCarcinogenesis, Nat RevCancer 8(1) (2008) 56-61.
    8 ( 1 ) ( [2008]
  • [19] J.H. Kim, Y.S. Kim, K. Park, S. Lee, H.Y. Nam, K.H. Min, H.G. Jo, J.H. Park, K. Choi, S.Y. Jeong, R.W. Park, I.S. Kim, K. Kim, I.C. Kwon, Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumorbearing mice, J Control Release 127(1) (2008) 41-9.
  • [15] V.P. Torchilin, Drug targeting, Eur J Pharm Sci 11 Suppl 2 (2000) S81-91.
    11 Suppl 2 ( [2000]
  • [130] Y. Yang, R. Hernandez, J. Rao, L. Yin, Y. Qu, J. Wu, C.G. England, S.A. Graves, C.M. Lewis, P. Wang, M.E. Meyerand, R.J. Nickles, X.W. Bian, W. Cai, Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas, Proc Natl Acad Sci U S A 112(47) (2015) E6525-34.
  • [12] A. Daka, D. Peer, RNAi-based nanomedicines for targeted personalized therapy, Adv Drug Deliv Rev 64(13) (2012) 1508-21.
  • [126] Z. Wang, X. Yan,CD146, a multi-functional molecule beyond adhesion,Cancer Lett 330(2) (2013) 150-62.
    330 ( 2 ) ( [2013]
  • [120] A. Hoeben, B. Landuyt, M.S. Highley, H. Wildiers, A.T. Van Oosterom, E.A. De Bruijn, Vascular endothelial growth factor and angiogenesis, Pharmacol Rev 56(4) (2004) 549-580.
  • [118] S.Y. Lee, M.S. Huh, S. Lee, S.J. Lee, H. Chung, J.H. Park, Y.K. Oh, K. Choi, K. Kim, I.C. Kwon, Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing, J Control Release 141(3) (2010) 339-346.
  • [117] S.J. Lee, A. Lee, S.R. Hwang, J.S. Park, J. Jang, M.S. Huh, D.G. Jo, S.Y. Yoon, Y. Byun, S.H. Kim, I.C. Kwon, I. Youn, K. Kim, TNF-alpha Gene Silencing Using Polymerized siRNA/Thiolated Glycol Chitosan Nanoparticles for Rheumatoid Arthritis, Mol Ther 22(2) (2014) 397-408.
  • [116] S.J. Lee, M.S. Huh, S.Y. Lee, S. Min, S. Lee, H. Koo, J.U. Chu, K.E. Lee, H. Jeon, Y. Choi, K. Choi, Y. Byun, S.Y. Jeong, K. Park, K. Kim, I.C. Kwon, Tumor-Homing Poly-siRNA/Glycol Chitosan Self-Cross-Linked Nanoparticles for Systemic siRNA Delivery in Cancer Treatment, Angew Chem Int Edit 51(29) (2012) 7203-7207.
  • [103] C.D. Spicer, C. Jumeaux, B. Gupta, M.M. Stevens, Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications, Chem Soc Rev 47(10) (2018) 3574-3620.
  • [100] F. Kratz, Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles, J Control Release 132(3) (2008) 171-83.
  • Why do cancers have high aerobic glycolysis ?
    4 ( 11 ) ( [2004]
  • Up-Regulation of PD-L1 , IDO , and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
    5 ( 200 ) ( [2013]
  • Tumour antigens recognized by T lymphocytes : at the core of cancer immunotherapy
    14 ( 2 ) ( [2014]
  • Tumor-targeting multifunctional nanoparticles for siRNA delivery : recent advances in cancer therapy
    3 ( 8 ) ( [2014]
  • Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    114 ( 8 ) ( [2009]
  • Tumor angiogenesis and antiangiogenic gene therapy for cancer ( Review )
    16 ( 1 ) ( [2018]
  • Theranostic designs of biomaterials for precision medicine in cancer therapy
    213 ( [2019]
  • The role of glutathione in cancer
    22 ( 6 ) ( [2004]
  • The reversal of drug-resistance in tumors using a drug-carrying nanoparticular system ,
    10 ( 9 ) ( [2009]
  • The metabolism of albumin-bound C14-labeled unesterified fatty acids in normal human subjects
    37 ( 11 ) ( [1958]
  • The blockade of immune checkpoints in cancer immunotherapy
    12 ( 4 ) ( [2012]
  • The Next ImmuneCheckpoint Inhibitors : PD-1/PD-L1 Blockade in Melanoma
    37 ( 4 ) ( [2015]
  • The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
    75 ( 5 ) ( [1993]
  • The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of MMP2 and MMP9
    11 ( 2 ) ( [2016]
  • Ten years of anti-vascular endothelial growth factor therapy
    15 ( 6 ) ( [2016]
  • Targeting neoantigens to augment antitumour immunity
    17 ( 4 ) ( [2017]
  • Targeted delivery systems of small interfering RNA by systemic administration
    22 ( 3 ) ( [2007]
  • Systemic siRNA delivery to tumors by cell-penetrating alpha-helical polypeptide-based metastable nanoparticles
    10 ( 32 ) ( [2018]
  • Synthesis and antitumor efficacy of a beta-glucuronidase-responsive albumin-binding prodrug of doxorubicin
    55 ( 9 ) ( 2012 ) 4516-20 .
  • Sunitinib in advanced pancreatic neuroendocrine tumors : latest evidence and clinical potential ,
    4 ( 1 ) ( [2012]
  • Specific Growth Rate versus Doubling Time for QuantitativeCharacterization of Tumor Growth Rate
    67 ( 8 ) ( [2007]
  • SPARC modulatesCell growth , attachment and migration of U87 gliomaCells on brain extracellular matrix proteins ,
    53 ( 2 ) ( [2001]
  • SPARC ExpressionCorrelates with Tumor Response to Albumin-Bound Paclitaxel in Head and NeckCancer Patients
    2 ( 2 ) ( [2009]
  • Reductive degradation behavior of bioreducible poly ( disulfide amine ) for enhancing SiRNA efficiency
    10 ( 8 ) ( [2010]
  • RNA Interference ( RNAi ) -Based Therapeutics : Delivering on the Promise ?
    56 ( [2016]
  • R.O . Pieper , Loss of tumor suppressor PTEN function increases B7-H1 expression
    glioma , Nat Med 13
  • Quantitation of doxorubicin uptake , efflux , and modulation of multidrug resistance ( MDR ) in MDR humanCancerCells ,
    324 ( 1 ) ( [2008]
  • Polyethylenimine-dermatan sulfateComplex , a bioactive biomaterial with unique toxicity toCD146-positiveCancerCells
    [2017]
  • P-selectin-mediated platelet activation promotes adhesion of non-smallCell lungCarcinomaCells on vascular endothelialCells under flow
    5 ( 4 ) ( [2012]
  • P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment
    8 ( 22 ) ( [2018]
  • Oxygenation of human tumors : evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements
    51 ( 12 ) ( [1991]
  • Overcoming cellular barriers for RNA therapeutics
    35 ( [2017]
  • Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice
    3 ( 3 ) ( [2013]
  • Oncogenic MicroRNAs : Key Players in Malignant Transformation
    7 ( 4 ) ( [2015]
  • O. Hamid , S. Bhatia , R. Martins , K. Eaton , S. Chen
    Alaparthy , J.F . Grosso
  • New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting ,
    127 ( 2 ) ( [2008]
  • Nano-based delivery of RNAi in cancer therapy
    16 ( 1 ) ( [2017]
  • Multiple functions of BCL-2 family proteins
    5 ( 2 ) [2013]
  • Molecular dynamics study of the IIA binding site in human serum albumin : influence of the protonation state of Lys195 and Lys199
    44 ( 2 ) ( [2001]
  • MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators ,
    28 ( 17 ) ( [2008]
  • Metronomic chemotherapy : new rationale for new directions
    7 ( 8 ) ( [2010]
  • Mechanisms , reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
    11 ( 4 ) ( [2000]
  • Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer
    27 ( 31 ) ( [2009]
  • Lipophilic siRNA targets albumin in situ and promotes bioavailability , tumor penetration , and carrier-free gene silencing
    114 ( 32 ) ( [2017]
  • Lipid-based nanoparticles as pharmaceutical drug carriers : from concepts to clinic
    26 ( 6 ) ( [2009]
  • L. Chen , Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of
    Sci Transl Med 4 (
  • K. Kim , Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to
    J Control Release 198 ( 2015
  • Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells
    2 ( 7 ) ( [1988]
  • In vivo delivery of miRNAs for cancer therapy : challenges and strategies
    81 ( [2015]
  • Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer ,
    140 ( [2017]
  • Implications of biochemical , cytokinetic , pharmacologic , and toxicologic relationships in the design of optimal therapeutic schedules
    54 ( 6 ) ( [1970]
  • ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors
    13 ( 7 ) ( [2016]
  • IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
    112 ( 9 ) ( [2015]
  • How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
    103 ( 8 ) ( [2010]
  • Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy
    10 ( [2015]
  • Heterogeneity of the tumor vasculature : the need for new tumor blood vessel type-specific targets
    29 ( 7 ) ( [2012]
  • H. Brahmbhatt , Sequential treatment of drugresistant tumors with targeted minicells containing siRNA or
    , Nat Biotechnol 27 ( 7 ) ( 2009
  • Glutathioneresponsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery
    152 ( 1 ) ( [2011]
  • Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging
    17 ) [2008]
  • Gene electrotransfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28 ,
    20 ( [2013]
  • Gene delivery through the use of a hyaluronateassociated intracellularly degradable cross-linked polyethyleneimine
    30 ( 29 ) ( [2009]
  • Factors affecting the clearance and biodistribution of polymeric nanoparticles
    5 ( 4 ) ( [2008]
  • Exploiting the enhanced permeability and retention effect for tumor targeting ,
    11 ( 17-18 ) ( [2006]
  • Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
    8 ( 327 ) ( [2016]
  • Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense : novel multicomponent delivery system
    64 ( 17 ) ( [2004]
  • Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma : largest singlecenter retrospective analysis
    7 ( 19 ) ( [2016]
  • Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy
    14 ( 4 ) ( [2014]
  • Dual Faces of IFNgamma in Cancer Progression : A Role of PD-L1 Induction in the Determination of Proand Antitumor Immunity
    22 ( 10 ) ( [2016]
  • Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo
    13 ( 6 ) ( [2011]
  • Disulfide-cleavage-triggered chemosensors and their biological applications
    113 ( 7 ) ( [2013]
  • Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts
    8 ( 1 ) ( [2002]
  • Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy : a comprehensive review of registration trials and future considerations
    6 ( 1 ) ( [2018]
  • Developing Anticancer Copper ( II ) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain
    12 ( 10 ) ( [2015]
  • Designing Prodrugs Based on Special Residues of Human Serum Albumin ,
    16 ( 9 ) ( [2016]
  • Designer vaccine nanodiscs for personalized cancer immunotherapy
    16 ( [2016]
  • Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
    9 ( 1 ) ( [2016]
  • Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
    8 ( 2 ) ( [2018]
  • Cozzio , R. Dummer , Martin C. Mihm , Jr. ,
    Flaherty , Markus H. Frank
  • Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells ,
    33 ( 3 ) ( [2005]
  • Combination cancer immunotherapy and new immunomodulatory targets
    14 ( 8 ) ( [2015]
  • Codelivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells
    5 ( 23 ) ( [2009]
  • Clinical blockade of PD1 and LAG3 -- potential mechanisms of action
    15 ( 1 ) ( [2015]
  • Cellular uptake and intracellular trafficking of oligonucleotides : implications for oligonucleotide pharmacology
    24 ( 2 ) ( [2014]
  • Cathepsin B as a cancer target
    17 ( 3 ) ( [2013]
  • Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy : A systematic review and meta-analysis
    53 ( [2017]
  • Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
    2 ( 1 ) ( [2018]
  • Cancer is a preventable disease that requires major lifestyle changes
    25 ( 9 ) ( [2008]
  • Cancer immunotherapies targeting the PD-1 signaling pathway
    24 ( 1 ) ( [2017]
  • Cancer drug resistance : an evolving paradigm
    13 ( 10 ) ( [2013]
  • Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway ,
    12 ( 11 ) ( [2018]
  • Breaking up the correlation between efficacy and toxicity for nonviral gene delivery , PNAS ( 2007 ) 14454 ? 14459
  • Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma
    184 ( 7 ) ( [2010]
  • Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
    25 ( 1 ) ( [2018]
  • Biomarkers of response to immune checkpoint blockade in cancer treatment
    130 ( [2018]
  • B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
    10 ( 15 ) ( [2004]
  • Atomic structure and chemistry of human serum albumin
    358 ( 6383 ) ( [1992]
  • Antibody-mediated delivery of anti ? KRAS-siRNA in vivo overcomes therapy resistance in colon cancer
    21 ( 6 ) ( [2015]
  • Antibody mediated in vivo delivery of small interfering RNAs via cellsurface receptors
    23 ( 6 ) ( [2005]
  • Anti-VEGF/VEGFR therapy for cancer : reassessing the target
    72 ( 8 ) ( [2012]
  • Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels
    116 ( 16 ) ( [2010]
  • Angiogenesis inhibitors in cancer therapy : mechanistic perspective on classification and treatment rationales
    170 ( 4 ) ( [2013]
  • Angiogenesis in cancer and other diseases
    407 ( 6801 ) ( [2000]
  • An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein ,
    18 ( 7 ) ( [2018]
  • Amphiphilic dendrimer engineered nanocarrier systems for Codelivery of siRNA and paclitaxel to matrix metalloproteinase-rich tumors for synergistic therapy
    10 ( 4 ) ( 2018 ) 238-254 .
  • Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor
    94 ( [2016]
  • Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy ,
    16 ( 9 ) ( 2016 ) 5503-13 .
  • . Wasik , Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive proteinCD274 ( PD-L1
    U S A 105 (
  • . Johnson , A.N . Shoushtari , Safety of resuming anti-PD-1 in patients with immune-related adverse events ( irAEs ) duringCombined
    anti-PD1 in metastatic melanoma ,
  • , Tumorassociated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune
    Med 8 ( 8 )
  • , T.C . Gangadhar , A. Patnaik , H. Zarour , A.M. Joshua , K.
    Algazi , C. Mateus ,
  • , R. Ross , F. Kabbinavar , Bevacizumab plus irinotecan , fluorouracil , and leucovorin for
    N Engl J Med 350
  • , R. Li , R.K. Vadlamudi , T.J.Curiel , Tumor-intrinsic PDL1 signals regulateCell
  • , R. Giavazzi , TheCombination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarianCarcinoma
    , Clin Cancer Res 9 ( 9 ) (
  • , J. O'Grady , R. Williams , D.L . Shawcross , S.Chokshi , Blockade of
    TIM3 restores innate and adaptive
  • , J. Drevs , D. Rognan ,C. Bissantz ,C. Hinderling , G. Folkers , I. Fichtner ,C. Unger , Probing theCysteine-34 position of endogenous serum albumin with thiol-binding
    Improved efficacy of an acid-sensitive